FAQs about delivery changes

Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Karyopharm Therapeutics Inc. - Common Stock (NQ:KPTI)

2.050 +0.080 (+4.06%)
Streaming Delayed Price Updated: 11:07 AM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karyopharm Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Analyst Ratings for Karyopharm Therapeutics ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗
 
Via Benzinga
News headline image
National Instruments, Virgin Galactic And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded slightly higher, with the Dow Jones gaining around 25 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript ↗
KPTI earnings call for the period ending September 30, 2022. 
Via The Motley Fool
News headline image
Expert Ratings for Karyopharm Therapeutics ↗
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: 
Via Benzinga
News headline image
Where Karyopharm Therapeutics Stands With Analysts ↗
Karyopharm Therapeutics (NASDAQ:KPTI) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Karyopharm Therapeutics Earnings Perspective: Return On Capital Employed ↗
  
Via Benzinga
News headline image
Analyst Ratings for Karyopharm Therapeutics ↗
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Recap: Karyopharm Therapeutics Q1 Earnings ↗
Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Incannex Healthcare (NASDAQ:IXHL) shares moved upwards by 30.7% to $5.19 during Friday's pre-market session. The market value of their outstanding shares is at $316.2 million. 
Via Benzinga
News headline image
Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
10 Best Medical Stocks Under $5 ↗
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the... 
Via Talk Markets
News headline image
Ryder System, Harrow Health And Other Big Gainers From Tuesday ↗
U.S. stocks closed mixed with the Dow Jones dropping around 125 points on Tuesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
HashiCorp, Pagerduty, Lululemon And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗
Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) surged 13.5% to $19.25 in pre-market trading. A consortium led by Hollysys Automation’s management is looking to take the US-listed company private... 
Via Benzinga
News headline image
Why Pagerduty Is Trading Higher By 9%; Here Are 28 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Karyopharm Therapeutics: Q2 Earnings Insights ↗
  Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's session saw 63 companies set new 52-week lows. 
Via Benzinga
News headline image
Karyopharm Shares Soar Following European Commission's Marketing Authorisation For Multiple Myeloma Candidate ↗
The European Commission (EC) has granted Marketing Authorisation for Karyopharm Therapeutics’ (NASDAQ: KPTI) lead candidate NEXPOVIO (selinexor) in combination with once-weekly bortezomib (Velcade) and... 
Via Benzinga
News headline image
Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗
  
Via Benzinga
News headline image
Karyopharm Shares Soar On FDA Fast Track Status, EU Orphan Medicinal Product Status To Preleukemia Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Karyopharm Therapeutics’ (NASDAQ: KPTI) lead asset Eltanexor as monotherapy for the treatment of patients with relapsed... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement ↗
 
Via Benzinga
News headline image
Looking Into Karyopharm Therapeutics's Return On Capital Employed ↗
Karyopharm Therapeutics (NASDAQ:KPTI) brought in sales totaling $47.67 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 206.92%, resulting in a loss of $41.40... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article